2026 NPPES data Pulmonary Disease Physician NPI 1962583096 M.D
Verify on CMS →

RAMA NANDIPATI, M.D

Pulmonary Disease Physician in MERCED, California. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
223
Medicare Part D claims · 86 beneficiaries · Pulmonary Disease Physician avg: 1K
Generic prescribing
42%
generic claims · 58% brand-name · higher generic rates reduce patient out-of-pocket costs

What the federal data shows

RAMA NANDIPATI, M.D filed 223 Medicare Part D claims in 2023 as a Pulmonary Disease Physician in MERCED, California, prescribing 42% generic.

223
Part D claims, 2023
42%
generic prescribing

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.

RAMA NANDIPATI, M.D's Medicare Part D volume vs every U.S. prescriber

Total Medicare Part D claims, 2023 — across all CMS prescribers nationally

223 49th percentile higher than 49% of 1,370,886 prescribers

0–200: 670,926 prescribers (49%). Below this entry. 200–400: 182,923 prescribers (13%). This entry sits in this band. 400–600: 90,619 prescribers (7%). Above this entry. 600–800: 56,224 prescribers (4%). Above this entry. 800–1,000: 40,919 prescribers (3%). Above this entry. 1,000–1,200: 31,827 prescribers (2%). Above this entry. 1,200–1,400: 26,224 prescribers (2%). Above this entry. 1,400–1,600: 21,710 prescribers (2%). Above this entry. 1,600–1,800: 19,072 prescribers (1%). Above this entry. 1,800–2,000: 16,451 prescribers (1%). Above this entry. 2,000–2,200: 213,991 prescribers (16%). Above this entry. This provider 0 2K+ every Part D prescriber (claims/yr), bucketed by value

Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Medicare Part D Prescriber Public Use File · 2023

Board-eligible specialty (heuristic — not verified)

RAMA NANDIPATI, M.D practices in an ABMS-board-eligible specialty but we don't have enough CMS-participation signals to confirm active board-certified status. Consult CertificationMatters.org (the official ABMS public lookup).

What does the federal data show about RAMA NANDIPATI, M.D?

Quality data not reported

NPI registry status

Active

Issued 10/17/2006

NPI 1962583096

Primary specialty

Pulmonary Disease Physician

Mid-sized

9,271 US NPIs in this specialty

Medicare Part D claims

223 85% vs specialty avg

2023 prescription claims

Specialty avg: 1,457

Specialty distribution in California

How Pulmonary Disease Physician compares to other specialties among California providers

California providers

Pulmonary Disease Physician share within California

1. Pulmonary Disease Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Pulmonary Disease Physician share within California

Specialty board-certification context

Estimated specialty board-certified rate — Pulmonary Disease Physician (ABMS / AOA reference)

Quality data not reported
Est. board-certified rate
78%
Pulmonary Disease Physician ABMS/AOA estimate

Est. board-certified rate (Pulmonary Disease Physician) — ABMS / AOA estimate

0%100%78%
Est. board-certified rate (Pulmonary Disease Physician) — ABMS / AOA estimate

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

RAMA NANDIPATI, M.D appears in the CMS NPPES registry as a Pulmonary Disease Physician provider holding M.D credentials at 450 E YOSEMITE AVE STE A, MERCED, CA, 95340, with a listed phone of (209) 725-1112. NPI 1962583096 was issued on 10/17/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what NANDIPATI most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 223 prescription claims written by this provider, covering 86 Medicare beneficiaries and totaling roughly $102K in drug spend, split 58% brand-name and 42% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy.

Pulmonary Disease Physician is a mid-sized specialty nationwide, with 9,271 enrolled providers across 53 states and an average of 1,457 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

450 E YOSEMITE AVE STE A
MERCED, CA 95340

Provider Details

NPI 1962583096
Specialty Pulmonary Disease Physician
Credentials M.D
Gender Male
NPI Issued 10/17/2006

License & disciplinary context — California MBC 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~150K California medical licensees in 2023 — they are NOT specific to RAMA NANDIPATI, M.D. To verify RAMA NANDIPATI, M.D's current license status, search the MBC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

576
Total board actions, California 2023
Across 556 cases
3.84
Actions per 1,000 licensees
California statewide rate
probation
Most common action type
186 cases

MBC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the California disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Brand-heavy

RAMA NANDIPATI, M.D — brand share 58.0%
Specialty average (est.)

58% brand-name claims vs 42% generic, on 223 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

223
Total Claims
$102K
Total Drug Cost
86
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
448
Total Day Supply
13,246
Brand vs Generic
58% brand / 42% generic
Brand Drug Cost
$99K

Patient Demographics

Average Patient Age
76.0 years
Avg HCC Risk Score
1.81
Gender Split
59% female / 41% male

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

What RAMA NANDIPATI, M.D prescribes most

Top Medicare Part D drugs by claim count, 2023

claims
Source CMS Medicare Part D Prescriber Public Use File As of 2023
Drug Claims
Montelukast Sodium
41
Albuterol Sulfate Hfa
Albuterol Sulfate
27
Trelegy Ellipta
Fluticasone/Umeclidin/Vilanter
16
Spiriva Respimat
Tiotropium Bromide
15
Atrovent Hfa
Ipratropium Bromide
13
Advair Hfa
Fluticasone Propion/Salmeterol
11
Breztri Aerosphere
Budesonide/Glycopyr/Formoterol
11
Flovent Hfa
Fluticasone Propionate
11

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Pulmonary Disease Physician Overview

How RAMA NANDIPATI, M.D fits within the Pulmonary Disease Physician landscape nationally.

9,271
Pulmonary Disease Physician Providers in US
53
States with Pulmonary Disease Physician
1,457
Avg Claims per Provider

RAMA NANDIPATI, M.D's 223 claims are below the specialty average of 1,457.

Nearby Pulmonary Disease Physician Providers in California

Other clinicians with the same primary specialty enrolled in California, drawn from the same CMS NPPES roster as NANDIPATI.

Compare Pulmonary Disease Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is RAMA NANDIPATI, M.D's specialty?
RAMA NANDIPATI, M.D specializes in Pulmonary Disease Physician and practices in MERCED, California. Credentials: M.D.
How much does RAMA NANDIPATI, M.D prescribe under Medicare Part D?
In 2023, RAMA NANDIPATI, M.D wrote 223 Medicare Part D claims totaling $102K in drug costs for 86 beneficiaries.
Where is RAMA NANDIPATI, M.D located?
RAMA NANDIPATI, M.D is located at 450 E YOSEMITE AVE STE A, MERCED, CA, 95340. Phone: (209) 725-1112.
What is RAMA NANDIPATI, M.D's NPI number?
RAMA NANDIPATI, M.D's National Provider Identifier (NPI) is 1962583096, issued on 10/17/2006.
Does RAMA NANDIPATI, M.D prescribe more brand-name or generic drugs?
RAMA NANDIPATI, M.D's prescribing is 58% brand-name and 42% generic drugs by claim count, with $99K in brand drug costs.
How many Pulmonary Disease Physician providers are there in the US?
There are 9,271 Pulmonary Disease Physician providers across 53 states in the US. The average Pulmonary Disease Physician provider writes 1,457 Medicare Part D claims per year.
What drugs does RAMA NANDIPATI, M.D prescribe most often?
Based on 2023 Medicare Part D data, RAMA NANDIPATI, M.D's most frequently prescribed drugs include Montelukast Sodium, Albuterol Sulfate Hfa, Trelegy Ellipta. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does RAMA NANDIPATI, M.D accept Medicare?
RAMA NANDIPATI, M.D appears in CMS Medicare data with 223 Part D claims and 86 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify RAMA NANDIPATI, M.D's credentials?
RAMA NANDIPATI, M.D's NPI is 1962583096 with credentials M.D. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology